PAU16 Antibody

What is PAUF/ZG16B and why is it significant in cancer research?

PAUF (pancreatic adenocarcinoma upregulated factor), also known as ZG16B (zymogen granule protein 16B), is a 156 amino acid secreted protein (~20-25 kDa) belonging to the jacalin-binding lectin family. Its significance stems from its overexpression in pancreatic adenocarcinoma and its binding capability to Toll-like receptors TLR2 and TLR4. Research has demonstrated that PAUF inhibits CXCR4-dependent, TLR2-mediated NF-kB activation and facilitates tumor growth, adhesiveness, and production of pro-tumorigenic cytokines . Recent studies have also shown its elevated expression is associated with poor prognosis and chemoresistance in epithelial ovarian cancer .

What are the primary applications for PAUF/ZG16B antibodies in research?

PAUF/ZG16B antibodies have been validated for several key research applications:

• Western blot analysis of tissue lysates (placenta, prostate, pancreatic tissues)

• Immunohistochemistry on paraffin-embedded sections (particularly cancer tissues)

• Detection of native and recombinant PAUF/ZG16B in biological samples

• Investigation of tumor progression mechanisms and cancer biomarker studies

For Western blot applications, the antibody has successfully detected PAUF/ZG16B at approximately 22 kDa in human tissue lysates under reducing conditions .

How specific is the PAUF/ZG16B antibody across different tissue types?

The PAUF/ZG16B antibody demonstrates high specificity across multiple human tissues. Immunohistochemical studies show distinct cytoplasmic and plasma membrane staining patterns in pancreatic cancer cells with minimal background in surrounding tissues . The antibody has been validated in placenta and prostate tissues by Western blot, showing consistent detection of the target protein. While PAUF expression appears restricted to primates, researchers should note that the related protein ZG16P (sharing ~25% amino acid sequence identity) is more widely expressed across species and may present cross-reactivity concerns in comparative studies.

What are the optimal conditions for Western blot detection of PAUF/ZG16B?

For optimal Western blot detection of PAUF/ZG16B, the following protocol has proven effective:

The specificity of the band should be verified using positive control tissues (placenta or pancreatic cancer tissue) and negative controls (tissues with low PAUF expression) .

What protocol modifications are needed for immunohistochemistry on pancreatic cancer tissues?

For effective immunohistochemical detection of PAUF/ZG16B in pancreatic cancer tissues, researchers should implement the following protocol:

• Fix tissue sections in formalin and embed in paraffin

• Cut sections at 5 μm thickness

• Perform heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (pH ~9.0)

• Block endogenous peroxidase activity with 3% hydrogen peroxide

• Apply primary antibody at 15 μg/mL concentration

• Incubate overnight at 4°C

• Use an HRP-DAB detection system for visualization

• Counterstain with hematoxylin

• Mount and observe for cytoplasmic and membrane staining patterns

This protocol has successfully localized PAUF/ZG16B to the cytoplasm and plasma membranes of cancer cells with high specificity .

How should PAUF/ZG16B antibodies be stored and handled to maintain activity?

To ensure optimal antibody performance and longevity:

• Store unopened antibody at -20 to -70°C for up to 12 months from receipt date

• After reconstitution, store at 2 to 8°C for up to 1 month under sterile conditions

• For longer storage after reconstitution (up to 6 months), aliquot and store at -20 to -70°C

• Avoid repeated freeze-thaw cycles by using a manual defrost freezer

• Allow antibody to equilibrate to room temperature before opening the vial

• Centrifuge the vial briefly before opening to ensure recovery of all material

What are common sources of false negative results when using PAUF/ZG16B antibodies?

False negative results in PAUF/ZG16B detection can stem from several methodological issues:

• Insufficient antigen retrieval for IHC applications - optimize pH and heating time

• Protein degradation during sample preparation - ensure fresh samples and adequate protease inhibitors

• Antibody denaturation due to improper storage - maintain proper temperature conditions

• Inadequate incubation time - extend primary antibody incubation to overnight at 4°C

• Insufficient blocking - increase blocking time or adjust blocking agent concentration

• Sample-specific interference - consider testing alternative lysis buffers or extraction methods

When encountering negative results, systematically evaluate each step while including positive control tissues (placenta or pancreatic cancer) to validate the protocol .

How can non-specific binding be reduced in PAUF/ZG16B immunoassays?

To minimize non-specific binding and improve signal-to-noise ratio:

• Optimize antibody concentration through titration experiments (start with 0.5-2 μg/mL range)

• Include 0.1-0.5% detergent (Tween-20 or Triton X-100) in washing buffers

• Extend blocking duration (2-3 hours at room temperature)

• Use alternate blocking agents (BSA, casein, or commercial blocker) if milk proteins cause background

• Implement additional washing steps (minimum 3 × 10 minutes) between reagent applications

• Pre-absorb the antibody with non-specific proteins if cross-reactivity is observed

• For IHC, use biotin-free detection systems if endogenous biotin causes background

How do you determine if observed signals represent PAUF/ZG16B or related proteins with similar epitopes?

Confirming signal specificity requires multiple validation approaches:

• Compare detection patterns with published PAUF/ZG16B expression profiles

• Perform parallel experiments with alternative antibody clones targeting different epitopes

• Include knockdown/knockout controls where PAUF/ZG16B expression is reduced

• Conduct peptide competition assays using recombinant PAUF/ZG16B protein

• Compare molecular weight with the expected size (22 kDa)

• Assess reactivity against the related ZG16P protein to rule out cross-reactivity

• Verify expression using orthogonal methods (qPCR, mass spectrometry)

How can PAUF/ZG16B antibodies be integrated into multiplexed cancer biomarker panels?

Multiplexed detection strategies for PAUF/ZG16B in cancer research include:

• Sequential immunofluorescence staining using antibodies with distinct species origins

• Complementing with antibodies against related cancer markers (e.g., TLR2, TLR4, NF-κB pathway components)

• Employing tyramide signal amplification for enhanced sensitivity in multiplex IHC

• Utilizing automated multispectral imaging platforms to quantify co-localization patterns

• Implementing mass cytometry (CyTOF) with metal-tagged antibodies for high-dimensional analysis

• Combining with laser capture microdissection to correlate protein expression with tissue morphology

• Developing multiplex ELISA panels for detecting PAUF/ZG16B alongside other secreted cancer biomarkers

What methodological approaches enable investigation of PAUF/ZG16B's role in TLR signaling pathways?

To investigate PAUF/ZG16B's interactions with TLR signaling pathways:

• Co-immunoprecipitation assays using PAUF/ZG16B antibodies to capture TLR2/TLR4 complexes

• Proximity ligation assays to visualize and quantify protein-protein interactions in situ

• ELISA-based binding studies with recombinant PAUF/ZG16B and TLR ectodomains

• Functional assays measuring NF-κB activation in the presence of PAUF/ZG16B and TLR ligands

• Phospho-specific antibody panels to track signaling cascade activation/inhibition

• siRNA-mediated knockdown of PAUF/ZG16B followed by TLR stimulation

• Reporter gene assays to quantify PAUF/ZG16B's effects on TLR-dependent transcription

How can researchers quantitatively analyze PAUF/ZG16B expression across different cancer stages?

Quantitative analysis approaches for PAUF/ZG16B expression include:

• Digital pathology and automated image analysis of IHC-stained tissues

  • Measure staining intensity, distribution, and subcellular localization

  • Compare with H-score or Allred scoring systems

• Tissue microarray analysis for high-throughput screening

  • Standardize staining across multiple patient samples

  • Correlate with clinicopathological parameters

• Western blot densitometry with appropriate controls

  • Normalize to housekeeping proteins

  • Use recombinant protein standards for absolute quantification

• Flow cytometry for detecting cellular PAUF/ZG16B in suspension samples

  • Establish fluorescence intensity scales with calibration beads

  • Correlate with other cellular markers

• Statistical analysis frameworks

  • Apply appropriate statistical tests for different data types

  • Consider multivariate analysis to account for confounding factors

How does the epitope mapping approach for PAUF/ZG16B antibodies compare with other therapeutic antibodies like PG16?

The epitope mapping strategies for PAUF/ZG16B differ substantially from those used for neutralizing antibodies like PG16:

For PAUF/ZG16B antibodies:

• Epitope mapping typically employs peptide arrays or fragment-based approaches

• Recombinant protein fragments with sequential deletions help identify binding regions

• Site-directed mutagenesis can pinpoint critical amino acids for antibody recognition

In contrast, for neutralizing antibodies like PG16 (anti-HIV):

• Crystallography and cryo-EM are often used to define binding at atomic resolution

• PG16 targets a conserved epitope in the V1/V2 region of HIV gp120

• Neutralization escape mutants help identify critical binding residues

Similarly, for HPV16 antibodies like 26D1:

• Chimeric virus-like particles with swapped surface loops are used to define epitope boundaries

• Epitope competition studies with established antibodies (like H16.V5) determine binding overlap

• Molecular docking predicts interaction interfaces

What methodological differences exist between evaluating PAUF/ZG16B antibodies and viral neutralizing antibodies?

The evaluation methods differ significantly based on antibody function:

For example, PG16 antibody efficacy is measured by its ability to neutralize HIV-1 at an NT50 of 0.585 ng/ml , while HPV16 antibodies like 26D1 are evaluated through their ability to recognize specific loops on the viral capsid surface .

What emerging technologies might enhance PAUF/ZG16B detection sensitivity and specificity?

Emerging technologies with potential to advance PAUF/ZG16B research include:

• Single-molecule detection platforms for improved sensitivity

  • Digital ELISA (Simoa) technology for sub-picogram detection

  • Single-molecule imaging techniques for spatial analysis

• CRISPR-engineered cellular models

  • Reporter cell lines with endogenous PAUF/ZG16B tagging

  • Precisely controlled expression systems for functional studies

• Advanced microscopy approaches

  • Super-resolution microscopy for subcellular localization

  • Expansion microscopy for enhanced spatial resolution

• Novel antibody engineering strategies

  • Bispecific antibodies targeting PAUF/ZG16B and companion biomarkers

  • Nanobodies for improved tissue penetration and reduced background

• Artificial intelligence-based image analysis

  • Deep learning algorithms for automated pattern recognition

  • Multi-parameter data integration from various detection methods

How might research on PAUF/ZG16B antibodies inform development of therapeutic approaches?

The research findings on PAUF/ZG16B antibodies suggest several potential therapeutic applications:

• Antibody-drug conjugates (ADCs) targeting PAUF/ZG16B-overexpressing cancer cells

• CAR-T cell therapies using PAUF/ZG16B-specific single-chain variable fragments

• Bispecific antibodies linking immune effector cells to PAUF/ZG16B-positive tumors

• Small molecule inhibitors designed to disrupt PAUF/ZG16B-TLR interactions

• RNA interference or antisense oligonucleotides targeting PAUF/ZG16B transcripts

• Predictive biomarker development for patient stratification in clinical trials

The established association between PAUF/ZG16B overexpression and poor prognosis/chemoresistance in epithelial ovarian cancer makes it a particularly valuable target for therapeutic development .

What are the recommended validation steps before implementing PAUF/ZG16B antibodies in a new experimental system?

Before implementing PAUF/ZG16B antibodies in a new experimental system, researchers should:

• Perform antibody titration experiments to determine optimal concentration

• Validate specificity through positive and negative control tissues

  • Pancreatic cancer tissue (positive control)

  • Normal tissues with low PAUF expression (negative control)

• Compare results with published expression patterns

• Include isotype control antibodies to assess non-specific binding

• Consider orthogonal validation using alternative detection methods

• Test preabsorption with recombinant PAUF/ZG16B to confirm specificity

• Evaluate lot-to-lot consistency if switching between antibody batches

How should researchers interpret contradictory results between different PAUF/ZG16B detection methodologies?

When faced with contradictory results between different detection methods:

• Evaluate the sensitivity thresholds of each method

  • Western blot may detect denatured epitopes not accessible in IHC

  • IHC preserves spatial information but may have lower sensitivity

• Consider protein modifications affecting detection

  • Post-translational modifications may alter antibody recognition

  • Sample preparation differences can expose different epitopes

• Analyze tissue/sample heterogeneity

  • Expression levels may vary across different regions of the same tissue

  • Consider microdissection for more precise analysis

• Integrate multiple detection methods

  • Combine protein and mRNA detection approaches

  • Use mass spectrometry for unbiased protein identification

• Design controlled experiments to test specific hypotheses explaining the discrepancy

  • Manipulate conditions to determine which factors influence detection